152 related articles for article (PubMed ID: 21847569)
1. Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Lowe S; Dean R; Ackermann B; Jackson K; Natanegara F; Anderson S; Eckstein J; Yuen E; Ayan-Oshodi M; Ho M; McKinzie D; Perry K; Svensson K
Psychopharmacology (Berl); 2012 Feb; 219(4):959-70. PubMed ID: 21847569
[TBL] [Abstract][Full Text] [Related]
2. Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum.
Cartmell J; Salhoff CR; Perry KW; Monn JA; Schoepp DD
Brain Res; 2000 Dec; 887(2):378-84. PubMed ID: 11134627
[TBL] [Abstract][Full Text] [Related]
3. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat.
Cartmell J; Perry KW; Salhoff CR; Monn JA; Schoepp DD
J Neurochem; 2000 Sep; 75(3):1147-54. PubMed ID: 10936197
[TBL] [Abstract][Full Text] [Related]
4. Comment on: "Effects of a novel mGlu(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid" (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, Psychopharmacology, 2012).
Seeman P
Psychopharmacology (Berl); 2012 May; 221(2):355-6; author reply 357-8. PubMed ID: 22411429
[No Abstract] [Full Text] [Related]
5. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Kinon BJ; Zhang L; Millen BA; Osuntokun OO; Williams JE; Kollack-Walker S; Jackson K; Kryzhanovskaya L; Jarkova N;
J Clin Psychopharmacol; 2011 Jun; 31(3):349-55. PubMed ID: 21508856
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ; Svensson KA; Johnson BG; Schoepp DD
J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625
[TBL] [Abstract][Full Text] [Related]
8. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Rorick-Kehn LM; Johnson BG; Knitowski KM; Salhoff CR; Witkin JM; Perry KW; Griffey KI; Tizzano JP; Monn JA; McKinzie DL; Schoepp DD
Psychopharmacology (Berl); 2007 Jul; 193(1):121-36. PubMed ID: 17384937
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
10. Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade.
Cartmell J; Perry KW; Salhoff CR; Monn JA; Schoepp DD
Neuropharmacology; 2001 Jun; 40(7):847-55. PubMed ID: 11378155
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat.
Mignot E; Laude D; Elghozi JL
J Neurochem; 1984 Mar; 42(3):819-25. PubMed ID: 6198472
[TBL] [Abstract][Full Text] [Related]
12. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.
Mehta MA; Schmechtig A; Kotoula V; McColm J; Jackson K; Brittain C; Tauscher-Wisniewski S; Kinon BJ; Morrison PD; Pollak T; Mant T; Williams SCR; Schwarz AJ
Psychopharmacology (Berl); 2018 Jul; 235(7):1875-1886. PubMed ID: 29564482
[TBL] [Abstract][Full Text] [Related]
13. Acute effect of 17 beta-estradiol and lithium on ovariectomized rat brain biogenic amines metabolism.
Morissette M; Paolo TD
J Psychiatr Res; 1996; 30(2):95-107. PubMed ID: 8816304
[TBL] [Abstract][Full Text] [Related]
14. Androgen inhibits neurotransmitter turnover in the medial prefrontal cortex of the rat following exposure to a novel environment.
Handa RJ; Hejna GM; Lorens SA
Brain Res; 1997 Mar; 751(1):131-8. PubMed ID: 9098576
[TBL] [Abstract][Full Text] [Related]
15. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection].
Yoshino K
No To Shinkei; 1982 Nov; 34(11):1099-106. PubMed ID: 6186264
[TBL] [Abstract][Full Text] [Related]
16. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
[TBL] [Abstract][Full Text] [Related]
17. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
Hjärpe J; Söderman E; Andreou D; Sedvall GC; Agartz I; Jönsson EG
Psychiatry Res; 2018 May; 263():30-34. PubMed ID: 29482043
[TBL] [Abstract][Full Text] [Related]
18. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
[TBL] [Abstract][Full Text] [Related]
19. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
Downing AM; Kinon BJ; Millen BA; Zhang L; Liu L; Morozova MA; Brenner R; Rayle TJ; Nisenbaum L; Zhao F; Gomez JC
BMC Psychiatry; 2014 Dec; 14():351. PubMed ID: 25539791
[TBL] [Abstract][Full Text] [Related]
20. Analysis of neurotransmitter metabolite concentrations in canine cerebrospinal fluid.
Vaughn DM; Coleman E; Simpson ST; Satjawatcharaphong C
Am J Vet Res; 1988 Aug; 49(8):1302-6. PubMed ID: 2459997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
